Researchers report that blocking KDM5A and KDM5B, chromatin-regulating enzymes, can strengthen antitumor innate immune responses in HHV-8-positive B-cell lymphomas (Kaposi’s sarcoma-associated herpesvirus). The study, published in npj Viruses, frames epigenetic control as a driver of immune signaling in the virus-associated lymphoma setting. The result points to chromatin readers/writers as actionable nodes for combination immunotherapy approaches, potentially pairing epigenetic inhibitors with agents that rely on host innate immune activation. While still preclinical, the work adds to a growing therapeutic theme: improving immune recognition by rewiring gene expression programs rather than targeting only surface antigens.